JP2019517803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517803A5 JP2019517803A5 JP2018565376A JP2018565376A JP2019517803A5 JP 2019517803 A5 JP2019517803 A5 JP 2019517803A5 JP 2018565376 A JP2018565376 A JP 2018565376A JP 2018565376 A JP2018565376 A JP 2018565376A JP 2019517803 A5 JP2019517803 A5 JP 2019517803A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- nucleic acid
- item
- exogenous nucleic
- modified non
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005260 human cell Anatomy 0.000 claims description 87
- 150000007523 nucleic acids Chemical group 0.000 claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 210000000056 organ Anatomy 0.000 claims description 19
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- 241000894007 species Species 0.000 claims description 15
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 14
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 14
- 108010078791 Carrier Proteins Proteins 0.000 claims description 12
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 12
- 108060003306 Galactosyltransferase Proteins 0.000 claims description 11
- 102000030902 Galactosyltransferase Human genes 0.000 claims description 11
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 108010022379 (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase Proteins 0.000 claims description 8
- 102100031504 Beta-1,4 N-acetylgalactosaminyltransferase 2 Human genes 0.000 claims description 8
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 8
- 101100111156 Homo sapiens B4GALNT2 gene Proteins 0.000 claims description 8
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 8
- 102000012064 NLR Proteins Human genes 0.000 claims description 8
- 108091005686 NOD-like receptors Proteins 0.000 claims description 8
- 230000030741 antigen processing and presentation Effects 0.000 claims description 8
- 239000010445 mica Substances 0.000 claims description 8
- 229910052618 mica group Inorganic materials 0.000 claims description 8
- 102000002164 CARD domains Human genes 0.000 claims description 6
- 108050009503 CARD domains Proteins 0.000 claims description 6
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 claims description 6
- 101710102605 MHC class I polypeptide-related sequence A Proteins 0.000 claims description 6
- 101710102608 MHC class I polypeptide-related sequence B Proteins 0.000 claims description 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 6
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 6
- 230000001605 fetal effect Effects 0.000 claims description 6
- 210000004153 islets of langerhan Anatomy 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 210000004738 parenchymal cell Anatomy 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims 17
- 210000002950 fibroblast Anatomy 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 210000003969 blast cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000287 oocyte Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 28
- 108091036066 Three prime untranslated region Proteins 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 4
- 108091008928 CXC chemokine receptors Proteins 0.000 description 4
- 102000054900 CXCR Receptors Human genes 0.000 description 4
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 4
- 101710140363 ICP47 protein Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 108700002010 MHC class II transactivator Proteins 0.000 description 2
- 102100026371 MHC class II transactivator Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 102000047279 human B2M Human genes 0.000 description 2
- 102000044459 human CD47 Human genes 0.000 description 2
- 108010082406 peptide permease Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021212142A JP2022031487A (ja) | 2016-06-14 | 2021-12-27 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2022129299A JP2022160703A (ja) | 2016-06-14 | 2022-08-15 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2024154774A JP2024178220A (ja) | 2016-06-14 | 2024-09-09 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2025015908A JP2025076449A (ja) | 2016-06-14 | 2025-02-03 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350048P | 2016-06-14 | 2016-06-14 | |
| US62/350,048 | 2016-06-14 | ||
| PCT/US2017/037566 WO2017218714A1 (en) | 2016-06-14 | 2017-06-14 | Genetically modified cells, tissues, and organs for treating disease |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212142A Division JP2022031487A (ja) | 2016-06-14 | 2021-12-27 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2022129299A Division JP2022160703A (ja) | 2016-06-14 | 2022-08-15 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517803A JP2019517803A (ja) | 2019-06-27 |
| JP2019517803A5 true JP2019517803A5 (enExample) | 2020-07-27 |
| JP7519660B2 JP7519660B2 (ja) | 2024-07-22 |
Family
ID=60663278
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565376A Active JP7519660B2 (ja) | 2016-06-14 | 2017-06-14 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2021212142A Pending JP2022031487A (ja) | 2016-06-14 | 2021-12-27 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2022129299A Pending JP2022160703A (ja) | 2016-06-14 | 2022-08-15 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2024154774A Pending JP2024178220A (ja) | 2016-06-14 | 2024-09-09 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2025015908A Pending JP2025076449A (ja) | 2016-06-14 | 2025-02-03 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212142A Pending JP2022031487A (ja) | 2016-06-14 | 2021-12-27 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2022129299A Pending JP2022160703A (ja) | 2016-06-14 | 2022-08-15 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2024154774A Pending JP2024178220A (ja) | 2016-06-14 | 2024-09-09 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
| JP2025015908A Pending JP2025076449A (ja) | 2016-06-14 | 2025-02-03 | 疾患を処置するための遺伝子改変された細胞、組織、および臓器 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190335726A1 (enExample) |
| EP (1) | EP3468356A4 (enExample) |
| JP (5) | JP7519660B2 (enExample) |
| KR (2) | KR20230110373A (enExample) |
| CN (2) | CN109640645B (enExample) |
| AU (1) | AU2017285224B2 (enExample) |
| CA (1) | CA3027428A1 (enExample) |
| WO (1) | WO2017218714A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10231817B2 (en) | 2013-09-24 | 2019-03-19 | Giner Life Sciences, Inc. | System for gas treatment of a cell implant |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| US11033666B2 (en) | 2016-11-15 | 2021-06-15 | Giner Life Sciences, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
| WO2018204867A1 (en) | 2017-05-04 | 2018-11-08 | Giner, Inc. | Robust, implantable gas delivery device and methods, systems and devices including same |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP4417212A3 (en) | 2018-10-19 | 2024-12-04 | Regents Of The University Of Minnesota | Transplant tolerance induction with carbodiimide treated tolerizing vaccine |
| EP3760718A1 (en) * | 2019-07-04 | 2021-01-06 | Medizinische Hochschule Hannover | Tissue for use as allogeneic or xenogeneic transplant and method for its production |
| CN111264469B (zh) * | 2020-02-27 | 2022-03-25 | 西安交通大学医学院第一附属医院 | 一种基因免疫诱导的甲状腺相关性眼病动物模型的构建方法及雷帕霉素类药物的应用 |
| WO2022005463A1 (en) * | 2020-06-30 | 2022-01-06 | National Yang-Ming University | A glia cell and neuron co-culture system and method |
| CN111500693B (zh) * | 2020-07-02 | 2020-09-22 | 中南大学 | 检测巨噬细胞中rfx1表达水平的试剂在制备巨噬细胞分型检测制剂中的应用 |
| EP4380627A1 (en) * | 2021-08-06 | 2024-06-12 | Rutgers, the State University of New Jersey | Method for producing genetically modified cells |
| EP4384544A1 (en) * | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| CN114958768B (zh) * | 2022-06-02 | 2023-03-24 | 健颐生物科技发展(山东)有限公司 | Fgf10旁分泌通用型人成纤维细胞制剂的制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156306A (en) * | 1994-08-17 | 2000-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pancreatic β-cells for allogeneic transplantation without immunosuppression |
| US5770201A (en) | 1994-12-23 | 1998-06-23 | Rijsuniversiteit Te Leiden | HA-2 antigenic peptide |
| AU723003C (en) * | 1995-08-04 | 2004-01-29 | General Hospital Corporation, The | Transgenic swine and swine cells having human HLA genes |
| JP4751493B2 (ja) | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
| FR2760023B1 (fr) | 1997-02-21 | 2004-05-07 | Commissariat Energie Atomique | Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications |
| EP1241931A4 (en) * | 1999-09-13 | 2004-12-29 | Univ Massachusetts | CLONING PIGS USING DONORATION CELLS OR NUCLEAR CELLS OF DIFFERENTIATED CELLS AND PRODUCING PLURIPOTENT PIGS |
| KR100417566B1 (ko) * | 1999-11-19 | 2004-02-05 | 한국생명공학연구원 | 체세포 핵치환 복제수정란의 대량생산방법 |
| WO2002070648A2 (en) * | 2000-11-17 | 2002-09-12 | Hematech, Llc | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates |
| CA2438501C (en) * | 2001-02-14 | 2014-09-16 | Leo T. Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| WO2003054150A2 (en) * | 2001-12-07 | 2003-07-03 | The Ohio State University Research Foundation | Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US20050123525A1 (en) | 2003-11-13 | 2005-06-09 | Ulrich Martin | Composition and method for inducing immune tolerance towards cell, tissue and/or organ transplants |
| KR20090068646A (ko) * | 2007-12-24 | 2009-06-29 | (주)엠젠 | Ｈｌａ-ｇ 유전자 및 ｄａｆ 유전자를 발현하는 형질전환복제 돼지 및 그의 제조 방법 |
| KR20100022684A (ko) * | 2008-08-20 | 2010-03-03 | (주)엠젠 | 세 개의 유전자를 발현하는 복합형질전환 복제 돼지 및 그의 제조 방법 |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP2184297A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| EP2184070A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| CA2745376A1 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| KR20170125406A (ko) | 2009-08-11 | 2017-11-14 | 상가모 테라퓨틱스, 인코포레이티드 | 표적화 변형에 대한 동형접합성 유기체 |
| AU2010282239A1 (en) * | 2009-08-14 | 2012-03-08 | Revivicor, Inc. | Multi-transgenic pigs for diabetes treatment |
| US8734786B2 (en) * | 2009-09-16 | 2014-05-27 | Northwestern University | Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection |
| WO2012009337A2 (en) * | 2010-07-12 | 2012-01-19 | Dana-Farber Cancer Institute, Inc. | Nlrc5 as a target to intervene mhc class 1-mediated immune responses |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
| NZ759163A (en) * | 2011-02-14 | 2023-03-31 | Revivicor Inc | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
| EP3450563A1 (en) | 2011-02-25 | 2019-03-06 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
| CN102911270A (zh) * | 2011-08-05 | 2013-02-06 | 浙江大学 | 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法 |
| KR102135601B1 (ko) * | 2012-03-29 | 2020-07-20 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 탈모 질환의 치료 방법 |
| WO2013188358A1 (en) * | 2012-06-12 | 2013-12-19 | The General Hospital Corporation | Miniature swine transgenic for one or more coagulation factors |
| JP6297559B2 (ja) * | 2012-07-31 | 2018-03-20 | バジル・エム・ハンタッシュＢａｓｉｌ Ｍ． ＨＡＮＴＡＳＨ | Ｈｌａｇ改変された細胞および方法 |
| US20140115728A1 (en) * | 2012-10-24 | 2014-04-24 | A. Joseph Tector | Double knockout (gt/cmah-ko) pigs, organs and tissues |
| CN104046593A (zh) * | 2013-03-14 | 2014-09-17 | 浙江大学 | 一种低免疫原性的人细胞及其制备方法 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA2928635C (en) * | 2013-11-28 | 2022-06-21 | Horizon Genomics Gmbh | Somatic haploid human cell line |
| US20160060655A1 (en) * | 2014-05-30 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to treat latent viral infections |
| SG10201911411YA (en) * | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| CN105586389A (zh) * | 2014-10-21 | 2016-05-18 | 天津华大基因科技有限公司 | 试剂盒及其在检测遗传性骨病基因中的用途 |
| BR112017008251B1 (pt) * | 2014-10-22 | 2022-02-22 | Indiana University Research And Technology Corporation | Usos de um tecido de um porco transgênico que compreende um gene a(1,3) galactosiltransferase, cmah e ß4galnt2 interrompido e de um produto relacionado com a pele, e, métodos para preparação de um material de transplante para xenoenxerto, para produção de um composto de interesse e para produzir um reagente de cultura de células |
| AU2015360502A1 (en) * | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| CN104789592A (zh) * | 2015-03-19 | 2015-07-22 | 中国食品药品检定研究院 | 一种制备α-1,3GT基因敲除的非人哺乳动物的方法及应用 |
-
2017
- 2017-06-14 KR KR1020237022996A patent/KR20230110373A/ko not_active Ceased
- 2017-06-14 JP JP2018565376A patent/JP7519660B2/ja active Active
- 2017-06-14 EP EP17814052.1A patent/EP3468356A4/en active Pending
- 2017-06-14 US US16/312,052 patent/US20190335726A1/en not_active Abandoned
- 2017-06-14 AU AU2017285224A patent/AU2017285224B2/en active Active
- 2017-06-14 CN CN201780049966.6A patent/CN109640645B/zh active Active
- 2017-06-14 CN CN202111165647.6A patent/CN114176043B/zh active Active
- 2017-06-14 WO PCT/US2017/037566 patent/WO2017218714A1/en not_active Ceased
- 2017-06-14 KR KR1020197001275A patent/KR20190017985A/ko not_active Ceased
- 2017-06-14 CA CA3027428A patent/CA3027428A1/en active Pending
-
2021
- 2021-12-27 JP JP2021212142A patent/JP2022031487A/ja active Pending
-
2022
- 2022-08-15 JP JP2022129299A patent/JP2022160703A/ja active Pending
-
2024
- 2024-09-09 JP JP2024154774A patent/JP2024178220A/ja active Pending
-
2025
- 2025-02-03 JP JP2025015908A patent/JP2025076449A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517803A5 (enExample) | ||
| CN109640645B (zh) | 用于治疗疾病的遗传修饰的细胞、组织和器官 | |
| US20210085720A1 (en) | Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy | |
| JP6830437B2 (ja) | 疾患を処置するための遺伝子改変された細胞、組織および臓器 | |
| Müller et al. | Transgenic pigs carrying cDNA copies encoding the murine Mx1 protein which confers resistance to influenza virus infection | |
| JP2018500897A5 (enExample) | ||
| CN105578876B (zh) | 制备表达hlai类的非人动物的方法 | |
| US7547522B2 (en) | Method to enrich for α(1,3)-galactosyltransferase null pig cells | |
| Perota et al. | Generation of cattle knockout for galactose‐α1, 3‐galactose and N‐glycolylneuraminic acid antigens | |
| Magliocca et al. | Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression | |
| JP6942466B2 (ja) | 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法 | |
| US12448437B2 (en) | Transplant tolerance induction with carbodiimide treated tolerizing vaccine | |
| KR20220132521A (ko) | 변형된 줄기세포 및 이의 사용 방법 | |
| JP2020524994A5 (enExample) | ||
| WO2020158924A1 (ja) | 母児間免疫寛容を誘導する方法 | |
| JP5745419B2 (ja) | 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 | |
| Salvaris et al. | Characterisation of transgenic pigs expressing a human T cell‐depleting anti‐CD2 monoclonal antibody | |
| US20230374448A1 (en) | Hypoimmunogenic Cells and Methods and Compositions for Their Production | |
| Pilunov et al. | Modification of Cytotoxic Lymphocytes with T Cell Receptor Specific for Minor Histocompatibility Antigen ACC-1Y | |
| CN1396832A (zh) | 抵制抗供体免疫的移植前适应器官 | |
| CN113439711A (zh) | 一种改造的巨噬细胞及其应用 | |
| EP3510861A2 (en) | Hypoallergenic food and medical products from genome edited livestock | |
| US20240294869A1 (en) | Pig xenotransplants into humans without chronic immunosuppression | |
| Voskoboynik et al. | Stem cells, chimerism and tolerance: Lessons from mammals and ascidians | |
| リアン クイーン | Studies on genome editing techniques using CRISPR/Cas9 in porcine embryos |